Search Results

Filter
  • 1-10 of  591 results for ""NEOVASCULARIZATION inhibitors""
Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request
Academic Journal

Vorolanib, sunitinib, and axitinib: A comparative study of vascular endothelial growth factor receptor inhibitors and their anti-angiogenic effects.

  • Authors : Bakri SJ; Department of Ophthalmology, Mayo Clinic, Rochester, Minnesota, United States of America.; Lynch J

Subjects: Axitinib*/Axitinib*/Axitinib*/pharmacology ; Sunitinib*/Sunitinib*/Sunitinib*/pharmacology ; Angiogenesis Inhibitors*/Angiogenesis Inhibitors*/Angiogenesis Inhibitors*/pharmacology

  • Source: PloS one [PLoS One] 2024 Jun 04; Vol. 19 (6), pp. e0304782. Date of Electronic Publication: 2024 Jun 04 (Print Publication: 2024).Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet

Record details

×
Academic Journal

Combination of Doxorubicin and Antiangiogenic Agents in Drug-Eluting Beads: In Vitro Loading and Release Dynamics in View of a Novel Therapeutic Approach for Hepatocellular Carcinoma.

  • Authors : Krokidis M; The 1st Department of Radiology, Areteion University Hospital, Medical School, National and Kapodistrian University of Athens, 76, Vas. Sophias Ave, 11528, Athens, Greece. .; Department of Diagnostic, Interventional and Pediatric Radiology (DIPR), Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland. .

Subjects: Doxorubicin*/Doxorubicin*/Doxorubicin*/administration & dosage ; Doxorubicin*/Doxorubicin*/Doxorubicin*/pharmacology ; Doxorubicin*/Doxorubicin*/Doxorubicin*/analogs & derivatives

  • Source: Cardiovascular and interventional radiology [Cardiovasc Intervent Radiol] 2024 May; Vol. 47 (5), pp. 661-669. Date of Electronic Publication: 2024 Apr 12.Publisher: Springer Verlag Country of Publication: United States NLM ID: 8003538 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

×
Academic Journal

Angiogenesis and anti-leukaemia activity of novel indole derivatives as potent colchicine binding site inhibitors.

  • Authors : Yao Y; Henan Provincial Key Laboratory of Pediatric Hematology, Children's Hospital Affiliated to Zhengzhou University, Zhengzhou University, Zhengzhou, China.; School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, Henan, China.

Subjects: Angiogenesis Inhibitors/Angiogenesis Inhibitors/Angiogenesis Inhibitors/*pharmacology ; Antineoplastic Agents/Antineoplastic Agents/Antineoplastic Agents/*pharmacology ; Colchicine/Colchicine/Colchicine/*antagonists & inhibitors

  • Source: Journal of enzyme inhibition and medicinal chemistry [J Enzyme Inhib Med Chem] 2022 Dec; Vol. 37 (1), pp. 652-665.Publisher: Taylor & Francis Country of Publication: England NLM ID: 101150203 Publication Model: Print Cited Medium: Internet ISSN: 1475-6374

Record details

×
Academic Journal

CM082, a novel VEGF receptor tyrosine kinase inhibitor, can inhibit angiogenesis in vitro and in vivo.

  • Authors : Dan H; Henan Eye Institute, Henan Eye Hospital, Henan Key Laboratory of Ophthalmology and Visual Science, Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, People's Hospital of Henan University, No. 7 Weiwu Road, Zhengzhou 450000, Henan, China.; Lei X

Subjects: Angiogenesis Inhibitors/Angiogenesis Inhibitors/Angiogenesis Inhibitors/*pharmacology ; Human Umbilical Vein Endothelial Cells/Human Umbilical Vein Endothelial Cells/Human Umbilical Vein Endothelial Cells/*drug effects ; Indoles/Indoles/Indoles/*pharmacology

  • Source: Microvascular research [Microvasc Res] 2021 Jul; Vol. 136, pp. 104146. Date of Electronic Publication: 2021 Feb 19.Publisher: Academic Press Country of Publication: United States NLM ID: 0165035 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

×
Academic Journal

Anlotinib for previously treated advanced or metastatic esophageal squamous cell carcinoma: A double-blind randomized phase 2 trial.

  • Authors : Huang J; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.; Xiao J

Subjects: Angiogenesis Inhibitors/Angiogenesis Inhibitors/Angiogenesis Inhibitors/*therapeutic use ; Esophageal Neoplasms/Esophageal Neoplasms/Esophageal Neoplasms/*drug therapy ; Esophageal Squamous Cell Carcinoma/Esophageal Squamous Cell Carcinoma/Esophageal Squamous Cell Carcinoma/*drug therapy

  • Source: Cancer medicine [Cancer Med] 2021 Mar; Vol. 10 (5), pp. 1681-1689. Date of Electronic Publication: 2021 Feb 14.Publisher: John Wiley & Sons Ltd Country of Publication: United States NLM ID: 101595310 Publication Model: Print-Electronic Cited Medium: Internet

Record details

×
Academic Journal

Structure-activity relationship studies of indolin-2-one derivatives as vascular endothelial growth factor receptor inhibitors and anticancer agents.

  • Authors : Yousefian M; Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran.; Department of Medicinal Chemistry, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.

Subjects: Neovascularization, Pathologic*; Angiogenesis Inhibitors/Angiogenesis Inhibitors/Angiogenesis Inhibitors/*pharmacology ; Indoles/Indoles/Indoles/*pharmacology

  • Source: Archiv der Pharmazie [Arch Pharm (Weinheim)] 2020 Dec; Vol. 353 (12), pp. e2000022. Date of Electronic Publication: 2020 Sep 03.Publisher: Wiley-VCH Verlag GmbH & Co. KGaA Country of Publication: Germany NLM ID: 0330167 Publication Model: Print-Electronic Cited Medium: Internet

Record details

×
Academic Journal

CM082, a novel angiogenesis inhibitor, enhances the antitumor activity of gefitinib on epidermal growth factor receptor mutant non-small cell lung cancer in vitro and in vivo.

  • Authors : Zhang K; Academy of Military Medical Science, Beijing, China.; Department of Lung Oncology, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, China.

Subjects: Drug Synergism* ; Mutation*; Angiogenesis Inhibitors/Angiogenesis Inhibitors/Angiogenesis Inhibitors/*pharmacology

  • Source: Thoracic cancer [Thorac Cancer] 2020 Jun; Vol. 11 (6), pp. 1566-1577. Date of Electronic Publication: 2020 May 05.Publisher: Wiley Publishing Asia Pty Ltd Country of Publication: Singapore NLM ID: 101531441 Publication Model: Print-Electronic Cited Medium: Internet

Record details

×
Academic Journal

Efficacy and safety of anlotinib, a multikinase angiogenesis inhibitor, in combination with epirubicin in preclinical models of soft tissue sarcoma.

  • Authors : Wang ZM; Department of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai, China.; Xiamen Branch, Zhongshan Hospital, Fudan University, Xiamen, China.

Subjects: Angiogenesis Inhibitors/Angiogenesis Inhibitors/Angiogenesis Inhibitors/*pharmacology ; Antibiotics, Antineoplastic/Antibiotics, Antineoplastic/Antibiotics, Antineoplastic/*pharmacology ; Apoptosis/Apoptosis/Apoptosis/*drug effects

  • Source: Cancer medicine [Cancer Med] 2020 May; Vol. 9 (10), pp. 3344-3352. Date of Electronic Publication: 2020 Mar 17.Publisher: John Wiley & Sons Ltd Country of Publication: United States NLM ID: 101595310 Publication Model: Print-Electronic Cited Medium: Internet

Record details

×
Academic Journal

Antiangiogenic therapy with Nintedanib affects hypoxia, angiogenesis and apoptosis in the ventral prostate of TRAMP animals.

  • Authors : da Silva RF; Department of Structural and Functional Biology, Institute of Biology, State University of Campinas (UNICAMP), P.O. Box 6109, Campinas, São Paulo, 13083-865, Brazil.; Department of Pharmaceutical Sciences, Skaggs School of Pharmacy, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.

Subjects: Apoptosis*/Apoptosis*/Apoptosis*/drug effects; Adenocarcinoma/Adenocarcinoma/Adenocarcinoma/*drug therapy ; Angiogenesis Inhibitors/Angiogenesis Inhibitors/Angiogenesis Inhibitors/*therapeutic use

  • Source: Cell and tissue research [Cell Tissue Res] 2020 Feb; Vol. 379 (2), pp. 407-420. Date of Electronic Publication: 2019 Aug 31.Publisher: Springer-Verlag Country of Publication: Germany NLM ID: 0417625 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

×
Academic Journal

Variable impact of three different antiangiogenic drugs alone or in combination with chemotherapy on multiple bone marrow-derived cell populations involved in angiogenesis and immunity.

  • Authors : Reguera-Nuñez E; Department of Medical Biophysics, University of Toronto, Toronto, ON, M5S 2J7, Canada.; Biological Sciences Platform, Sunnybrook Research Institute, Room S-217, 2075 Bayview Ave, Toronto, ON, M4N 3M5, Canada.

Subjects: Bone Marrow Cells*/Bone Marrow Cells*/Bone Marrow Cells*/immunology ; Bone Marrow Cells*/Bone Marrow Cells*/Bone Marrow Cells*/pathology; Angiogenesis Inhibitors/Angiogenesis Inhibitors/Angiogenesis Inhibitors/*pharmacology

  • Source: Angiogenesis [Angiogenesis] 2019 Nov; Vol. 22 (4), pp. 535-546. Date of Electronic Publication: 2019 Aug 28.Publisher: Springer Country of Publication: Germany NLM ID: 9814575 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-7209

Record details

×
  • 1-10 of  591 results for ""NEOVASCULARIZATION inhibitors""